Compare CHT & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHT | ZTS |
|---|---|---|
| Founded | 1996 | 1952 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9B | 31.2B |
| IPO Year | 2003 | 2012 |
| Metric | CHT | ZTS |
|---|---|---|
| Price | $46.08 | $81.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $154.18 |
| AVG Volume (30 Days) | 111.6K | ★ 6.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.02% | 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 1.42 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $5.37 | $5.63 |
| Revenue Next Year | $3.23 | $4.77 |
| P/E Ratio | ★ $26.66 | $57.25 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $39.28 | $73.82 |
| 52 Week High | $47.03 | $167.38 |
| Indicator | CHT | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 65.36 | 41.22 |
| Support Level | $41.79 | $74.35 |
| Resistance Level | N/A | $82.34 |
| Average True Range (ATR) | 0.59 | 2.21 |
| MACD | 0.14 | 1.81 |
| Stochastic Oscillator | 95.32 | 83.23 |
Chunghwa Telecom Co Ltd is Taiwan's integrated telecom operator, providing fixed-line, wireless, and Internet and data services. The company's reportable segments are: Consumer Business, Enterprise Business, International Business, and Others. The majority of its revenue comes from the Consumer Business, which focuses on individual and home-centric businesses, such as mobile, fixed broadband, Wi-Fi, IPTV (MOD), and OTT services. The Enterprise business offers IDC, cloud, cybersecurity, 5G, AIoT, data, AI, enterprise digital transformation, and system integration services to businesses, and the International business segment represents services offered to international customers. Geographically, the company generates maximum revenue from its business in Taiwan.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.